2 Feb 2017 16:37
SalvaRx Group plc
("SalvaRx" or "the Company")
Intensity Therapeutics Inc.
The Company notes the recent article in MoneyWeek Magazine about SalvaRx and Intensity Therapeutics Inc., ("Intensity") in which the Company has an 8.5 per cent. interest. The article incorrectly stated that Intensity had dosed its first patient in clinical trials. Intensity expects to dose its first patient shortly at which point a further notification will be made by SalvaRx which will contain full details of the trial including the timeframe for results.
SalvaRx Group plc | |
Ian Walters (Chief Executive) | Tel: +1 203 441 5451 |
Northland Capital Partners Limited Nominated Adviser and Broker | Tel: +44 (0) 20 3861 6625
|
Matthew Johnson / Edward Hutton (Corporate Finance) | |
John Howes (Corporate Broking) |
Peterhouse Corporate Finance Limited Joint Broker Lucy Williams / Duncan Vasey | Tel: +44 (0) 20 7469 0932 |
SALV.L (SALV)